The Reality of Cancer Care: Why Patients Are Looking Beyond Their Borders
When you are diagnosed with cancer, the first instinct is to trust your local healthcare system. But for millions of patients around the world, that trust collides with a harsh reality: long waitlists, prohibitive costs, or limited treatment options.
Consider these facts:
In the United Kingdom, only 68.6% of cancer patients started treatment within the 62-day target in February 2026. An estimated 107,000 patients waited longer than 62 days in 2025. (Source: Cancer Research UK, April 2026)In Canada, the median wait from GP referral to treatment reached 30.0 weeks in 2024 — the longest ever measured. (Source: Fraser Institute, 2024)In the United States, even with insurance, cancer patients face average out-of-pocket costs of $42,000 in the first year alone. Without insurance, treatment can cost $150,000-300,000+ annually. (Source: American Cancer Society, 2025)In the Middle East, access to advanced therapies like CAR-T, proton therapy, and novel immunotherapies may require travel abroad entirely.For these patients — and thousands more from France, Australia, Russia, and Southeast Asia — China has emerged as a compelling alternative. Not as a “second best” option, but often as the best option: faster access, world-class technology, and costs that are 30-70% lower than Western equivalents.
This guide is a comprehensive overview of cancer treatment in China for international patients. It covers the types of treatments available, the top hospitals, real costs, patient stories, and exactly how the process works.
The Chinese Oncology Landscape: What Makes It Different
Volume That scale of care
China treats more cancer patients than any country on Earth. In 2023, there were an estimated 4.8 million new cancer diagnoses in China (Source: National Cancer Center, China, 2024). This volume has created a healthcare system uniquely equipped to handle cancer at scale.
The Cancer Hospital of the Chinese Academy of Medical Sciences (Beijing) handles over 500,000 outpatient visits annually.Fudan University Shanghai Cancer Center treats over 50,000 new patients each year.Sun Yat-sen University Cancer Center (Guangzhou) sees over 600,000 outpatient visits annually.This volume translates directly into clinical expertise. Chinese oncologists perform more procedures, administer more cycles of therapy, and manage more complex cases than their counterparts in almost any other country.
Advanced treatment modalities available
China offers the full spectrum of modern cancer treatments:
Surgical oncology — open, laparoscopic, and robotic-assisted. China is the world’s second-largest market for robotic surgery, with over 500,000 robot-assisted procedures performed in 2025 (Source: da Vinci / Chinese hospital data).Chemotherapy — all standard regimens available. Domestic generic versions significantly reduce costs.Radiation therapy — IMRT, IGRT, SBRT, SRS (Gamma Knife, CyberKnife), and particle therapy (proton, carbon ion, heavy ion).Immunotherapy — PD-1/PD-L1 inhibitors (domestic and imported), CTLA-4 inhibitors, and bispecific antibodies. China is now the global leader in PD-1 clinical trials.Targeted therapy — all major tyrosine kinase inhibitors, monoclonal antibodies, and oral targeted agents. Many available as lower-cost domestic versions.CAR-T cell therapy — approved for B-cell malignancies (Yescarta, Tecartus) and myeloma. Multiple clinical trials for solid tumors. FasTCAR technology reduces manufacturing to 24-36 hours (vs. 2-4 weeks in the West).Hormonal therapy — for breast, prostate, and other hormone-sensitive cancers.Traditional Chinese Medicine (TCM) — adjunctive treatments for symptom management, immune support, and quality of life.Clinical trials — China now conducts the second-highest number of oncology clinical trials globally, after only the United States. For many patients, this means access to cutting-edge therapies years before they reach other markets.### Cost advantage
The price gap is not small — it is transformative.
| Treatment | US Cost (USD) | China Cost (USD) | Savings |
|---|---|---|---|
| Chemotherapy (per session) | $5,000-30,000 | $200-1,200 | 90-96% |
| Immunotherapy (PD-1 per cycle) | $15,000-25,000 | $3,000-4,000 | 75-85% |
| CAR-T therapy (total) | $370,000-475,000 | $50,000-80,000 | 80-87% |
| Proton therapy (full course) | $60,000-150,000 | $30,000-50,000 | 50-67% |
| Radiation (30 fractions IMRT) | $30,000-70,000 | $4,000-8,000 | 85-90% |
| Targeted therapy (monthly) | $10,000-20,000 | $2,000-5,000 | 60-80% |
Sources: Sinoaid Medical Tourism Cost Comparison, Guangdong Provincial Health Commission data, Chinese hospital direct pricing. FDA pricing data.
These savings are not achieved by cutting quality. They are the result of fundamentally lower operational costs (physician salaries, hospital overhead, malpractice insurance), government pricing controls, generics-first drug policy, and high-volume efficiency.
Top Cancer Hospitals in China for International Patients
Southern Region
Sun Yat-sen University Cancer Center (中山大学肿瘤防治中心 / SYSUCC) — Guangzhou – National ranking: #1 in South China, Top 3 nationally – Annual volume: 600,000+ outpatient visits, 50,000+ new patients – Specialties: All major cancer types; particularly strong in nasopharyngeal, lung, breast, colorectal, liver – International patient services: Dedicated international department, English-speaking coordinators, clinical trial access – Estimated treatment start: 7-14 days from first contact
Nanfang Hospital — Department of Oncology (Guangzhou) – National ranking: A++++ (top tier) – Annual volume: 260,000+ international patients cumulatively from 92 countries – Specialties: Hematological malignancies, solid tumors, hepatobiliary oncology – International services: Dedicated international center since 1979, multilingual, direct insurance billing, Halal dining
The First Affiliated Hospital of Guangzhou Medical University — Guangzhou – Specialty rank: #1 nationally for respiratory medicine – Best for: Lung cancer, thoracic oncology
Shenzhen People’s Hospital — Oncology Department — Shenzhen – Growing international patient capacity – Hong Kong cross-border collaboration
Beijing Region
Cancer Hospital, Chinese Academy of Medical Sciences (中国医学科学院肿瘤医院) – National ranking: #1 in China for oncology – Annual volume: 500,000+ outpatient visits – Best for: Complex and rare cancers, clinical trials, multi-modality treatment
Peking University Cancer Hospital (北京大学肿瘤医院) – National ranking: Top 3 for oncology – Annual volume: 400,000+ outpatient visits – Best for: Gastrointestinal cancers, breast cancer, lymphoma
Shanghai Region
Fudan University Shanghai Cancer Center (复旦大学附属肿瘤医院) – National ranking: Top 3 for oncology – Annual volume: 50,000+ new patients per year – Best for: Breast cancer, colorectal cancer, gynecological oncology
Shanghai Chest Hospital (上海市胸科医院) – Best for: Lung cancer, thoracic oncology, esophageal cancer
Hainan RegionSpecialized Centers
Boao Lecheng International Medical Tourism Pilot Zone — Hainan – Access to 560+ FDA/EMA-approved oncology drugs – CAR-T, proton therapy, novel immunotherapies – Zero-tariff pricing on imported therapies – Real-world data clinical programs – Partner hospitals include Ruijin Hospital Hainan, West China Lecheng Hospital
Cancer-Specific Considerations for International Patients
Breast Cancer
China offers comprehensive breast cancer care including mastectomy, breast-conserving surgery, reconstruction, and all standard systemic therapies (chemotherapy, targeted therapy, hormonal therapy, immunotherapy).
Domestic biosimilar advantage: Trastuzumab (Herceptin) biosimilars are available at 60-80% less than the brand drug in Western markets.
Cost estimate for Stage II HER2+ breast cancer (total): $20,000-40,000 vs. $100,000-200,000 in the US.
Lung Cancer
China sees the highest lung cancer incidence in the world, giving Chinese thoracic oncologists unparalleled experience.
Domestic advantage: Multiple domestic PD-1 inhibitors (sintilimab, toripalimab, camrelizumab) are approved for lung cancer at 20-30% of Keytruda’s US price. All standard EGFR, ALK, and ROS1 targeted agents available.
Cost estimate for Stage IV NSCLC immunotherapy (6 months): $12,000-24,000 vs. $90,000-150,000 in the US.
Liver Cancer
Liver cancer is one of China’s highest-incidence cancers, particularly due to HBV prevalence. Chinese hepatobiliary surgeons have world-leading experience.
Domestic advantage: All standard TACE, radiofrequency ablation, Sorafenib, Lenvatinib, and immunotherapy combinations available. Domestic PD-1 plus bevacizumab biosimilar combinations significantly cheaper.
Cost estimate for HCC treatment (3 months, TACE + targeted therapy): $8,000-15,000 vs. $40,000-80,000 in the US.
Nasopharyngeal Carcinoma (NPC)
NPC is particularly common in southern China, and Chinese ENT and radiation oncology departments have unmatched volume and expertise in this challenging cancer.
Cost estimate for NPC treatment (radiation + chemo): $10,000-20,000 vs. $50,000-100,000 in the US.
The Patient Journey: What to Expect
Step 1: Initial Contact (Days 1-3)
You contact myMedVia and submit your medical records — biopsy reports, pathology slides, imaging (in DICOM format if possible), blood work, and treatment history. Our medical team reviews your case within 48 hours.
Step 2: Hospital Matching (Days 3-5)
Based on your diagnosis, cancer type, stage, and treatment history, we match you with the most appropriate hospital and oncology team. You receive three options with detailed justifications.
Step 3: Treatment Plan & Cost Estimate (Days 5-7)
The hospital’s oncology team reviews your records and provides a preliminary treatment plan with a transparent cost estimate. MyMedVia reviews the estimate and ensures no hidden fees.
Step 4: Medical Visa (Days 7-10)
The hospital issues a medical invitation letter (S2 visa application). We guide you through the visa required documents and coordinate with the Chinese embassy or consulate in your country.
Step 5: Travel & Arrival (Days 10-14)
You travel to China. MyMedVia arranges airport pickup, accommodation near the hospital, and in-person interpretation during all medical appointments.
Step 6: Diagnostic Confirmation (Days 14-17)
Upon arrival, the hospital conducts any necessary confirmatory diagnostics — PET-CT, biopsy review, blood tests. Results are typically available within 24-48 hours.
Step 7: Treatment Initiation (Days 14-21)
Treatment begins according to the finalized plan. Chemotherapy can start within 24-48 hours. Radiation treatment planning takes 2-3 days with first fraction at China’s major cancer centers.
Total time from first contact to first treatment: 2-3 weeks.
Real Patient Story: Sarah from Canada
Sarah, a 45-year-old mother of two from Vancouver, was diagnosed with triple-negative breast cancer in July 2025. Her oncologist recommended a treatment plan including surgery, chemotherapy, and immunotherapy.
The wait: 12 weeks for surgery, followed by 8 more weeks to start chemotherapy. Total timeline was estimated at 8+ months before she would complete active treatment.
“I couldn’t wait that long. Triple-negative is aggressive. Every week I waited, I felt the cancer growing.”
Sarah contacted myMedVia in August 2025. Within 10 days, she had: – A consultation with a breast oncology team at Fudan University Shanghai Cancer Center – A treatment plan: neoadjuvant chemotherapy with pembrolizumab, followed by surgery, followed by adjuvant capecitabine – A total cost estimate of $28,000 (all medical + travel + accommodation for 4 months)
She flew to Shanghai in September 2025. Her first chemotherapy infusion was administered within 48 hours of arrival.
“I went from ‘I might have cancer, what do I do’ to receiving treatment in less than three weeks. In Canada, I would have been waiting three more months just to start.”
How myMedVia Supports Your Cancer Journey
Fast-track Access ($300)
Medical record review within 48 hoursHospital matching to top oncology centersPriority appointment schedulingMedical visa invitation letterTreatment plan and cost estimate### Full Concierge ($1,000)
Everything in Fast-track plus:Airport pickup and accommodation bookingIn-hospital interpretation during all appointmentsDedicated patient coordinator for your entire stayCoordination of follow-up care and telemedicineAssistance with insurance claims## Is China Right for Your Cancer Treatment?
China is not the right choice for every patient. Here is a honest framework:
Good fit: – Patients facing long waitlists (4+ weeks) in their home system – Patients with cancers where China has particular expertise (lung, liver, gastric, NPC, esophageal, breast) – Patients seeking treatments not yet available in their home country (CAR-T, proton, novel immunotherapies) – Patients for whom cost is a significant barrier to treatment – Patients who are willing to travel for 2-12 weeks for treatment
Less suitable: – Patients with highly unstable acute conditions requiring immediate emergency intervention – Patients who are medically unfit for travel – Patients who have severe mobility or cognitive issues that make international travel unsafe – Patients whose specific rare cancer is better studied in another center of excellence
Getting Started
The only way to know if China is right for you is to ask. myMedVia offers a free, no-obligation case evaluation:
Submit your medical recordsReceive a hospital recommendation and cost estimate within 48 hoursCompare with your local optionsMake an informed decisionReady to get started? From your first consultation to recovery back home, myMedVia is with you every step of the way. Contact our patient coordinator →
Fast · Affordable · Certain